$0.34
-0.02 (-5.78%)
Open$0.36
Previous Close$0.36
Day High$0.36
Day Low$0.33
52W High$2.11
52W Low$0.27
Volume—
Avg Volume1.06M
Market Cap8.35M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,270.3% upside
Current
$0.34
$0.34
Target
$8.04
$8.04
$5.03
$8.04 avg
$9.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.65M | 5.72M | 5.36M |
| Net Income | 307.3K | 283.7K | 353.7K |
| Profit Margin | 5.4% | 5.0% | 6.6% |
| EBITDA | 445.8K | 473.3K | 433.9K |
| Free Cash Flow | 346.8K | 407.6K | 312.1K |
| Rev Growth | +24.0% | +14.6% | +14.6% |
| Debt/Equity | 0.71 | 0.92 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |